Log in with your email address username.


[Correspondence] Routine molecular profiling of patients with NSCLC – Authors’ reply

We thank Verena Schildgen and Oliver Schildgen for their thoughtful and critical comment on our report.1 We agree that our paper mainly reflects the French national programme for biomarkers in lung cancer and thus cannot be extensively extrapolated to other countries and other health systems. Our aim was to provide basic data for a large number of patients (the largest cohort published so far) rather than in-depth analysis for selected patients. We provide a clear and unbiased picture of the incidence of six major biomarkers in daily practice patients.